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Abstract
The uncontrolled reproduction of free-roaming feral cats contributes to overpopulation and associated concerns regarding their
welfare and impact on public health and the environment. Nonsurgical fertility control that could be administered to feral cats in
the field would be a powerful tool for cat population control. The objective was to test the efficacy and duration of activity of a
single-dose GnRH immunocontraceptive vaccine (GonaCon™) on the fertility of adult female laboratory cats. Vaccinated cats
(n  15) received a single injection of vaccine containing a GnRH-KLH conjugate (200 g) emulsified in a mycobacterial and
oil adjuvant on study Day 0. Sham-treated cats (n  5) received a single injection containing all vaccine components except the
GnRH-KLH conjugate. A breeding trial started on study Day 120. Vaccinated cats had a longer time to conception (median 39.7
mo) compared to sham-treated cats (4.4 mo; P  0.001). A total of 93% of vaccinated cats remained infertile for the first year
following vaccination, whereas 73, 53, and 40% were infertile for 2, 3, and 4 y, respectively. At study termination (5 y after a
single GnRH vaccine was administered), four cats (27%) remained infertile. The GnRH antibody titers declined more rapidly in
short-term responding cats with  2 y of infertility (n  4), compared to long-term responding cats that experienced fertility
control for2 y (n 11) (P 0.05). Non-painful but persistent late-onset granulomatous injection site masses appeared 2 y after
initial vaccination in five cats. We concluded that GnRH immunocontraception is an ideal candidate for further development for
feral cat control.
© 2011 Elsevier Inc. All rights reserved.
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1. Introduction
Unowned free-roaming (feral) cats number in the
millions nationally and exist throughout the world [1].
Their uncontrolled reproduction contributes to cat over-
population and associated concerns regarding their im-
pact on public health and the environment [2]. In parts
of the world where progressive animal control re-
sources are not available, measures such as poisoning
and shooting are still used to control cats [3]. Surgical
sterilization followed by return to the colony is an
increasingly popular method of controlling feral cat
populations, but is expensive, labor-intensive, highly
technical, and limited in scale [4,5].
Nonsurgical fertility control that could be adminis-
tered to feral cats in the field would be a powerful tool
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for cat population control. Control of free-roaming spe-
cies is often aimed at the level of the population, rather
than at specific individual animals. Treatment must be
efficacious in a high proportion of the population, but it
is not essential that every treated animal be rendered
infertile. Feral cats are wary of humans, and once
trapped and released, are unlikely to return for repeated
trapping episodes. A practical fertility control tech-
nique for feral cats would induce permanent or multi-
year duration of action following a single treatment in
the majority of animals treated.
Vaccines aimed at reproductive targets are one ap-
proach to nonlethal control of overabundant free-roam-
ing species. Overcoming tolerance to self antigens and
induction of durable immunity without the use of re-
peated booster vaccines are substantial challenges for
the development of immunocontraceptive vaccines. A
commonly used contraceptive antigen in wildlife is the
zona pellucida. In previous studies, we demonstrated
that vaccinating against the zona pellucida was ineffec-
tive in preventing pregnancy in cats [6,7]. Subse-
quently, we showed in a short-term study that a single
dose of GnRH vaccine in a mycobacterial and oil emul-
sion (GonaCon™) effectively blocked testosterone pro-
duction and spermatogenesis for at least 6 mo in a
majority of vaccinated adult male cats [8]. This was
apparently the first report to suggest that fertility con-
trol may be achievable in cats following a single vac-
cination against a reproductive self antigen.
We hypothesized that long-term fertility control in
cats can be induced by immunological blockade of
GnRH activity. The purpose of this study was to test the
efficacy and duration of activity of single-dose GnRH
immunocontraception on the fertility of adult female
cats.
2. Materials and methods
2.1. Cats
Twenty-four 8- to 14-mo-old specific-pathogen-free
female domestic shorthair cats were acquired from a
commercial vendor (Liberty Research, Waverly, NY,
USA). Cats were group-housed in one large enriched
room with raised resting benches, maintained at ambi-
ent temperatures between 21 and 23 °C, and exposed to
controlled lighting (explained later). Food and water
were available ad libitum. The experimental design was
approved by the University of Florida Institutional An-
imal Care and Use Committee, and facilities were ac-
credited by the Association for Assessment and Ac-
creditation of Laboratory Animal Care. All cats and
their offspring underwent surgical sterilization and
were adopted to private homes at the conclusion of the
study.
Upon arrival, the 24 cats were housed for 30 d in a
photoperiod regimen (8 h light: 16 h dark) that is
inhibitory for estrous cyclicity. Forty-six days prior to
treatment (Day 46), the photoperiod regimen was
reversed to 16 h light: 8 h dark, which is permissive for
estrous cyclicity within 15 d in most cats [9,10]. In cats,
behavioral estrus occurs in conjunction with elevated
concentrations of estradiol-17 secreted by developing
follicles. Progesterone concentrations rise significantly
within 4 d after ovulation, regardless of whether or not
fertilization has occurred [9,10]. Serum progesterone
and estradiol-17 concentrations were measured on
Day 64, and then every other day from Day 46 to
Day 26. The magnitude and duration (Day  20
pg/mL) of elevated estradiol-17 concentrations in
each cat were used to confirm normal photoperiod sen-
sitivity and estrous cyclicity in cats selected for this
study.
2.2. Vaccine construction
A GnRH vaccine was constructed using a synthetic
GnRH peptide with the sequence [pEHWSYGLRPGGC-
SH] produced by the Fmoc/tBU protection method
(Global Peptide Services, Fort Collins, CO, USA). Im-
munogenicity was enhanced by coupling GnRH pep-
tides to a protein carrier, keyhole limpet hemocyanin
(KLH; Pierce Biotechnology, Rockford, IL, USA), in a
1:3 GnRH:KLH mass ratio. The first 10 amino acids
represent the native GnRH molecule and “pE” signifies
pyroglutamate. One glycine was added at the C-termi-
nus as a spacer and a cysteine was added to ensure
consistent alignment of the peptide to the maleimide-
activated KLH. The aqueous-based GnRH-KLH conju-
gate (200 g) was combined in a 1:1 ratio by volume
with an emulsifying adjuvant, AdjuVac™, which was
produced by modifying a USDA-licensed Johne’s dis-
ease vaccine containing inactivated Mycobacterium
avium in mineral oil (Mycopar®; Fort Dodge Animal
Health, Fort Dodge, IA, USA). This GnRH vaccine
(GonaCon™, USDA, Pacarello, ID, USA) is licensed
as a “restricted-use pesticide” for prevention of estrous
cyclicity in white-tail deer.
2.3. Treatment
Twenty cats were selected for use in the GnRH
vaccination study based upon estrus induction follow-
ing an increase in light to 16 h per day. These 20 cats
were randomized based upon a similar peak estradiol-
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17 concentrations in response to long-day photope-
riod into a sham treatment group (n  5) and a vacci-
nation group (n  15). The sham-treated group
received placebo injections containing all components
except the GnRH-KLH conjugate. The treatment group
received vaccines containing 200 g GnRH-KLH.
Vaccines were administered intramuscularly under
general anesthesia. Brief anesthesia was induced by
administration of isoflurane (IsoFlo®; Abbott Labora-
tories, North Chicago, IL, USA) by face mask. The hair
of the right cranial thigh was clipped, and the injection
site was cleaned with 70% isopropyl alcohol. The vac-
cine (0.5 mL) was injected into the quadriceps muscle
group. This site was selected to avoid critical structures
such as the sciatic nerve in the event of a vaccine
reaction. This site is also accessible when cats are
resting in a crouched position, making it one of the
likely injection targets in nonsedated cats in the field.
The right pinna was tattooed with a treatment code for
permanent identification.
Potential reactions to vaccination were evaluated by
daily physical examination, including inspection of the
injection site, and measurement of body temperature
for 1 wk following treatment. The injection site was
inspected at the time of each monthly blood sample
collection throughout the study.
2.4. Breeding trial
The effects of treatment on fertility were evalu-
ated in a breeding trial beginning 4 mo after treat-
ment and continuing until each cat became pregnant
or until 60 mo post-treatment, whichever came first.
The daily photoperiod was alternated between the
estrus-inhibiting short-day regimen (16 h dark:8 h
light) and the estrus-inducing long-day regimen (8 h
dark:16 h light). The cats were exposed to short-day
photoperiod from Days 0 to 120, and from Days 330
to 360 (8% of post-treatment time). For the remain-
der of the study, the cats were exposed to long-day
photoperiod. The switch from short-day photoperiod
to long-day photoperiod was intended to induce es-
trus in any of the cats that were capable of an estrous
response. A breeding male was housed continuously
with the females during the long-day photoperiods
beginning on Day 120. Four breeding males were
alternated, to reduce the chance that inter-cat behav-
ioral incompatibility would affect breeding success.
Time-lapse videography was used to monitor breed-
ing activity during lighted hours. The recordings
were reviewed daily and the number of attempted
and successful breedings was recorded.
Time to conception was defined as the interval
between treatment Day 0 and fertilization date,
which was estimated by subtracting the average
length of cat gestation (63 d) from parturition date.
Fertility was defined as full-term pregnancy. Litter
size was defined as the number of total births (live
and stillborn). Fecundity was defined as the number
of live births. Pregnancy was scored as a treatment
failure, and the cats were removed from the study
after parturition. Short-term response to GnRH im-
munocontraception was defined as fertility control
for two y or less, whereas a long-term response was
defined as fertility control lasting more than 2 y after
the single vaccination.
2.5. Blood collection
Blood (4 mL) was collected by jugular venipuncture
monthly into serum separator tubes for determination of
GnRH antibody titer and progesterone concentration. In
addition, blood was collected every other day during an
interval of 20 d following change from short-day photo-
period to long-day photoperiod beginning on Days 120
and 360 (for determination of serum concentrations of
estradiol-17 and progesterone). Serum was separated by
centrifugation and stored at 20 °C pending analysis.
2.6. Detection of GnRH antibodies
Serum was tested for GnRH antibodies using an
enzyme-linked immunoabsorbant assay (ELISA). The
96-well plates (Thermo Electron Corporation, Wal-
tham, MA, USA) were coated with BSA-GnRH and
blocked with PBS buffer containing steelhead salmon
serum (SEA BLOCK; Pierce Biotechnology, Rockford,
IL, USA). Cat serum was added to wells in two-fold
dilutions starting at 1:1,000. Two negative controls
(buffer without cat serum and pre-vaccination cat
serum) and one positive control (serum from a cat
with a known high antibody titer) were included on
each plate. The GnRH antibodies were detected with
goat anti-cat IgG (Sigma Chemical Co., St. Louis,
MO, USA) followed by rabbit anti-goat IgG conju-
gated with horseradish peroxidase (Sigma Chemical
Co.), and color development with tetramethylbenzi-
dine/phosphate-citrate buffer (Sigma Chemical Co.).
Sulfuric acid (2M) was added to each well to stop the
reaction. Absorbance was read at 450 nm with a
Dynatech MR 5000 ELISA plate reader (Dynatech
Laboratories Inc., Alexandria, VA, USA). The end-
point titers were defined as the dilution at which the
absorbance was twice the absorbance of the pre-
vaccination cat serum.
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2.7. Determination of serum concentrations of
estradiol-17 and progesterone
Serum samples were analyzed for total estradiol-17
and progesterone by radio-immunoassay (Coat-A-
Count®; Diagnostic Products Corporation, Los Ange-
les, CA, USA) according to the manufacturer’s instruc-
tions. In each run, controls included human serum with
three concentrations of estradiol-17 (57, 127, and 934
pg/mL) and progesterone (1.78, 3.4, and 18.3 ng/
mL).The manufacturer reports an assay sensitivity for
estradiol-17 of 8 pg/mL with inter-assay CV (coeffi-
cient of variation) of 4 to 8% and intra-assay CV of 4
to 7%. Progesterone assay sensitivity was reported to
be 0.02 ng/mL with inter-assay CV of 4 to 10% and
intra-assay CV of 2 to 9%.
2.8. Body weight and composition
It has been well-documented that cats gain weight
and percent body fat after ovariectomy [11,12], but it is
unknown if immunocontraception has the same effect.
To evaluate for this effect, an estimation of body fat
was made by radiographic evaluation of the abdominal
falciform fat pad on Day 420. Cats were sedated with
medetomidine 40 mcg/kg IM (Domitor; Pfizer Animal
Health, New York, NY, USA) and imaged in right
lateral recumbency using computed radiography
(Kodak, Rochester, New York, USA). The depth (mm)
of the falciform fat pad was measured by dropping a
perpendicular line from the center of the body of the
12th thoracic vertebra to the ventral body wall and
measuring the distance between the caudoventral angle
of the liver and the ventral body wall. The area (mm2)
of the fat pad was defined as the area outlined by the
line used for the depth measurement, the ventral border
of the liver, the caudal aspect of the diaphragm, and the
ventral body wall (Fig. 1).
2.9. Statistical analysis
Differences in the median time to conception be-
tween the sham-treated group and the GnRH-vacci-
nated group were determined by the Kaplan-Meier sur-
vival analysis log rank test. Mean  SEM were
calculated for normally distributed data (monthly titers,
body weight, fat pad measurements, litter size), and
groups were compared with the Kruskal-Wallis one
way ANOVA. Median and interquartile range (IQR)
were calculated for non-normally distributed data (peak
titer, titer at conception), and groups were compared
with the Mann-Whitney rank sum test. Differences
were considered significant when P  0.05. All tests
were performed using SigmaStat® statistical software,
version 3.1 (SPSS Inc., Chicago, IL, USA).
3. Results
3.1. Reactions to treatment
Body temperature in all of the cats remained normal
after treatment, and there was no inflammation or ten-
derness at the injection sites. One vaccinated cat died
Fig. 1. The size of the falciform fat pad in female cats was assessed radiographically as an estimate of body fat content. The depth of the fat pad
was measured at the level of the center of the T12 vertebral body (dashed line) from the ventral border of the liver to the ventral abdominal wall.
The area of the fat pad was measured as the area confined by the ventral border of the liver, the caudal surface of the diaphragm, the ventral
abdominal wall, and the line used for the depth of the fat pad measurement. The solid line shows the boundaries for measuring the area of the
fat pad.
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suddenly 45 d after treatment; necropsy revealed no
gross or histological abnormalities to explain the death.
This cat was replaced with a 2 y old cat of proven
fertility from the colony and vaccinated with the GnRH
vaccine according to the standard protocol.
Twenty-four months after immunization, it was dis-
covered that one of the cats had a firm 4 cm  5 cm
mass at the vaccination site. No pain reaction was
elicited on palpation of the mass. A biopsy revealed
granulomatous inflammation with interlesional acid-
fast bacteria (Fig. 2). Aerobic, anaerobic, and myco-
bacterial cultures were negative. Smaller single or mul-
tiple masses  1 cm in diameter developed at the
injection site of four other cats. The size of the masses
in all five cats waxed and waned for the duration of the
study, but the cats never appeared painful and the
lesions never drained. Three of the cats with masses
never became pregnant, and the other two became preg-
nant at 863 and 1212 d, respectively. No masses were
observed in the sham-treated cats.
3.2. Breeding trial
All four breeding male cats sired litters during the
study. The first male cat was introduced on Day 120
post-treatment at the beginning of a second long-day
photoperiod. All sham-treated cats displayed behav-
ioral signs of estrus and were receptive to breeding
attempts by the male within 10 days of the change to
long-day photoperiod. Time-lapse videography re-
vealed that the male bred each of the sham-treated cats
at least 15 times between Days 122 and 155. One
sham-treated cat was observed breeding in two inter-
vals during gestation (Days 7 to 11 and Days 25 to 26
of gestation). Four (27%) vaccinated cats that displayed
estrous behavior and began breeding on Days 128, 418,
469, and 504 were classified as having a short-term
response to GnRH vaccination.
Based on an average gestation period of 63 d, parturi-
tion date was used to estimate the date of conception. The
GnRH-vaccinated group had a longer median time (P 
0.001) to conception following treatment (39.7 mo) com-
pared to the sham-treated group (4.4 mo; Fig 3). All five
sham-treated cats became pregnant 7–28 d (study Days
127–148) after the male cat was introduced. One short-
term responder cat was bred in three successive periods of
estrus between Days 129–164, before becoming pregnant
on Day 164, whereas the other three short-term responder
cats became pregnant during their first estrus following a
prolonged vaccine-induced anestrous period (Days 418,
469, and 504, respectively).
Eleven (73%) cats were classified as long-term re-
sponders with fertility control lasting greater than two y
following a single GnRH vaccination. A total of 93% of
vaccinated cats remained infertile for the first year
following vaccination, 73% for 2 y, 53% for 3 y, and
40% for 4 y (Fig. 3). At the time the study was termi-
nated (5 y after a single GnRH vaccine was adminis-
tered), four cats (27%) had never become pregnant.
There was a small but significant difference in fe-
cundity (live births) in the GnRH-vaccinated group (2.6 
Fig. 2. Biopsy (stained with hematoxylin and eosin) of a subcutane-
ous injection-site nodule in a cat which appeared 24 mo following a
single vaccination against GnRH. There was granulomatous inflam-
mation, with acid fast bacilli evident within the lesion (inset). Five
cats developed persistent late-onset, non-painful, injection-site nod-
ules.
Fig. 3. Fertility control in cats. Vaccinated cats (n  15) received a
single injection of vaccine containing a GnRH-KLH conjugate (200
g) in a mycobacterial and oil emulsion on study Day 0. Sham-
treated cats (n  5) received a single injection containing all vaccine
components except the GnRH-KLH conjugate (n  5). A breeding
trial was commenced on study Day 120. Vaccinated cats had longer
time to conception (median 39.7 mo) compared to sham-treated cats
(4.4 mo; P  0.001).
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0.3) compared to the sham-treated group (3.8  0.4;
P 0.04; Table 1). There was no difference in the number
of stillborn kittens between the groups (P  0.9).
3.3. GnRH antibody titers
All vaccinated cats developed detectable GnRH an-
tibodies (Table 1). The magnitude of GnRH antibody
titers 1 mo after vaccination was similar in cats that
responded to vaccination for  2 y (short-term re-
sponding group) and those that responded for  2 y
(long-term responding group; Fig. 4). However, anti-
body titers decreased more quickly in the short-term
responding group and remained lower at each monthly
point beginning 5 mo post-vaccination (P 0.05). Peak
Table 1
Time to conception, litter size, and GnRH antibody titers in individual sham-treated cats (n  5), short-term responding cats (n  4), and
long-term responding cats (n  11). Four cats remained infertile for the entire duration of the 5 y study.
Cat Conception (Day) Peak GnRH titer GnRH titer at conception Live births Still births Injection-site reaction
Sham 1 127 0 0 3 0 No
Sham 2 128 1000 1000 3 1 No
Sham 3 131 0 0 4 0 No
Sham 4 137 0 0 5 1 No
Sham 5 148 4000 4000 4 0 No
Short-term 1 164 32,000 8000 3 0 No
Short-term 2 418 32,000 4000 2 0 No
Short-term 3 469 128,000 4000 3 0 No
Short-term 4 504 128,000 4000 1 0 No
Long-term 1 863 128,000 16,000 3 0 Yes
Long-term 2 995 128,000 64,000 2 1 No
Long-term 3 1078 128,000 64,000 3 1 No
Long-term 4 1212 256,000 128,000 4 0 Yes
Long-term 5 1343 256,000 128,000 4 0 No
Long-term 6 1640 128,000 0 3 1 No
Long-term 7 1684 256,000 0 1 3 No
Long-term 8 NA 256,000 NA NA NA No
Long-term 9 NA 128,000 NA NA NA Yes
Long-term 10 NA 256,000 NA NA NA Yes
Long-term 11 NA 256,000 NA NA NA Yes
Fig. 4. GnRH antibody titers (mean  SEM) in sham-treated cats (n  5), short-term responding cats (n  4), and long-term responding cats
(n  11) during the first 2 y following treatment with a single sham or GnRH vaccine. The GnRH antibody titers declined more rapidly in
short-term responding cats with  2 y of infertility compared to long-term responding cats that experienced fertility control for 2 y (*P  0.05).
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GnRH antibody titers were higher in the long-term
responding group (median 256,000, IQR 128,000–
256,000) than in the short-term responding group (me-
dian 80,000, IQR 32,000–128,000; P  0.02; Table 1).
Most cats that became pregnant had antibody titers of
16,000 or less at the time of conception, but four cats
had antibody titers of 64,000–128,000. Antibody titers
in the four cats that never became pregnant were
128,000–256,000 at the end of the study, 5 y after the
single GnRH vaccination.
3.4. Hormone concentrations
Nineteen of the cats selected for the study responded
to long-day photoperiod prior to treatment, with a surge
in estradiol-17  20 pg/mL for at least four consec-
utive days and peak estradiol-17  40 pg/mL for at
least 1 d. The remaining cat responded to long-day
photoperiod with elevation of estradiol-17 from base-
line, but exceeded 20 pg/mL on 1 d only. Six of 20 cats
had an increase in serum progesterone  2 ng/mL
following the change to long-day photoperiod prior to
treatment, indicating pseudopregnancy following es-
trus, even though the male cat had not yet been admit-
ted to the colony. A cycle of 1 mo of short-photoperiod
followed by return to long-day photoperiod on Day 360
failed to trigger behavioral estrus, breeding attempts, or
increases in serum progesterone in any of the 14 vac-
cinated cats that remained in the study at that time.
The first elevation of progesterone  2 ng/mL dur-
ing monthly testing was associated with pregnancy in
14 of the cats (5 sham-treated cats and 9 vaccinated
cats). In two other cats, both long-term responders,
episodic non-fertile progesterone increases were de-
tected during Days 1500 to 1590 and Days 1410 to
1650 before conception followed by term pregnancy
occurred on Days 1640 and 1684, respectively. Proges-
terone elevation was also observed on Days 1230, 1650
to 1680, and 1830, respectively, in three of the cats that
never became pregnant during the 5 y study period.
Elevated progesterone was never detected in one of the
cats that never became pregnant.
3.5. Body weight and composition
At the time of treatment on Day 0, there were no
significant differences (P  0.5) in body weight among
the sham-treated (3.5  0.2 kg), short-term responder
(3.2  0.2 kg), and long-term responder (3.3  0.1 kg)
groups. Similar to cats undergoing surgical steriliza-
tion, long-term responder cats had a higher percentage
gain in body weight than sham-treated cats and short-
term responder cats (P  0.02; Table 2). Weight gain
was also reflected in abdominal fat content. The mean
falciform fat pad depth for the long-term responder
group was greater than the mean for the sham-treated
group (P  0.02) and the short-term responder group
(P  0.03). The area of the falciform ligament was not
significantly different among groups (P  0.1).
4. Discussion
The vaccine used in this study induced fertility con-
trol in 100% of cats following a single injection, but
duration of contraception varied from 5 mo to  5 y.
Infertility was maintained for 3 y in approximately half
of the cats and for more than 5 y in a quarter of the cats.
Response to vaccination was accompanied by a cessa-
tion in estrous cyclicity and with weight gain, similar to
cats undergoing surgical sterilization via ovariectomy.
This is apparently the first study to demonstrate
multi-year fertility control following a single vaccina-
tion in cats. Although permanent sterilization is ideal,
the relatively short life-span of many free-roaming feral
cats suggests that a contraceptive that blocks fertility
for several years in a high proportion of cats may be
successful in reducing the population. Most models
propose that more than 70% of the female cats in a
population must be rendered infertile to trigger a neg-
ative population growth rate [13–15], but one model
found that focusing a control program on juvenile cats
and utilizing a contraceptive having 3 y duration of
activity would stop population growth when just 60%
of the female cats were treated [16].
Duration of infertility was associated with persis-
tence of high GnRH antibody titers. Most cats with an
antibody titer  16,000 remained infertile. However,
several cats, all long-term responders, successfully re-
Table 2
Body weight gain and abdominal fat (mean  SEM) in cats as a
function of response to GnRH vaccination. Body weight was
measured at the time of treatment on Day 0 and again on Day 420
and the percentage change in weight calculated. Abdominal
falciform fat pad depth and area were measured from lateral
radiographs made on Day 420. Long-term responding cats (n 
11) gained more weight and had greater fat pad depth than sham-
treated (n  5) and short-term responding cats (n  4).
Response group Body weight
gain (%)
Fat pad
depth (mm)
Fat pad
area (mm2)
Sham (n  5) 15  7 19  2 728  145
Short-term responses
(n  4)
4  10 19  2 839  172
Long-term responses
(n  11)
40  6* 28  3* 1193  148
* P  0.02.
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produced in the presence of antibody titers as high as
256,000. We inferred that there is no absolute contra-
ceptive antibody titer that is predictive of infertility and
that other factors also influence the contraceptive effect
of GnRH immunization in female cats. In a previous
study in male cats, antibody titers of  32,000 were
associated with suppression of serum testosterone con-
centrations and spermatogenesis consistent with immu-
nocastration [8]. Immunocontraception targeting GnRH
appeared to be more effective in female cats than in
male cats. All female cats in the current study experi-
enced a delay in conception compared to sham-treated
cats, whereas only 67% of male cats demonstrated
infertility as determined by semen analysis in the pre-
vious study [8]. Higher efficacy in females has been
observed in other species including feral swine [17],
white-tailed deer [18], and domestic dogs (L. Miller,
unpublished).
In addition to suppression of estrus, GnRH immu-
nocontraception may have additional effects on repro-
duction. In this study, litter sizes in cats that recovered
fertility were slightly smaller than litter sizes in sham-
treated cats. Whether this is a transient phenomenon in
the first pregnancy following recovery of fertility, is
related to the older age of the vaccinated cats at the time
of pregnancy, or is a persistent effect possibly related to
the continued presence of GnRH antibodies is un-
known, as cats were removed from the study following
delivery of their first litter.
Granulomatous injection-site reactions containing
acid fast bacteria, presumably from the adjuvant, were
identified in five long-term responding cats. This evi-
dence of an ongoing immune response may explain the
ability of this depot vaccine to create durable immunity
against a self antigen in a large proportion of cats in the
absence of a booster vaccination protocol. Granuloma-
tous and neoplastic masses at the injection site and
systemic inflammatory responses have been previously
reported in cats receiving zona pellucida antigens in the
presence of mycobacteria and oil (Freund’s complete or
incomplete adjuvants) [6,19]. The production of dura-
ble immunity using non-replicating vaccines is a great
challenge, particularly against a small self antigen such
as GnRH [20]. Adjuvants and carrier proteins with
T-cell epitopes that stimulate the immune system to
react against the target antigen do so in the context of
inducing a local inflammatory response. As a species,
cats are at increased risk for development of life-threat-
ening sarcomas at the site of inflammation resulting
from vaccination and other injections [21]. In another
study of GnRH immunocontraception in cats, all kittens
vaccinated with a GnRH vaccine or placebo containing
oil developed acute transient injection-site masses [22].
The initial reactions resolved, but examination of in-
jection sites following booster vaccines up to 20 mo
later was not reported. Consideration should be given to
the development of vaccine formulations that reduce
the risk of injection-site reactions and possible sarcoma
formation in cats. However this concern should be
balanced against the very real threats to the welfare of
cats associated with their uncontrolled reproduction and
with control programs that rely on long-term confine-
ment or culling. Risk assessments associated with non-
surgical fertility control should also include a compar-
ison with the known morbidity and mortality associated
with surgical sterilization, particularly in owned cats in
which the benefit to the individual is a higher priority
than population control.
GnRH has many of the characteristics of an ideal
contraceptive target. Hypothalamic GnRH is a deca-
peptide “master hormone” that controls downstream
pituitary and gonadal responses in both male and fe-
male mammals. In the absence of GnRH stimulation,
the gonadal hormones estrogen, progesterone, and tes-
tosterone are suppressed and gamete maturation does
not occur [8,22,23]. This results in infertility, elimina-
tion of repeated estrous cycles that can lead to uterine
disease and mammary carcinoma, and reduction of un-
desirable nuisance behaviors such as fighting, roaming,
spraying, and estrous calling. This is an advantage over
contraceptive targets (such as zona pellucida) that block
fertility, but not necessarily estrous cyclicity. The avail-
ability of a single product effective in both males and
females following a single dose is also an advantage,
because it eliminates the need to re-trap animals for
repeat treatments, to maintain an inventory of multiple
different products, to target trapping campaigns to one
sex, or even to determine what sex a trapped cat is. The
vaccine used in this study was approved in September
2009 for control of white-tail deer by the Environmen-
tal Protection Agency, which regulates the use of “pes-
ticides,” including nonlethal products for use in feral
and “pest” species [24]. The vaccine has not been
approved for use in any other species at this time,
including feral cats.
Many feral cats are too unsocialized for safe han-
dling. In contrast to surgical sterilization, the GnRH
vaccine used in this study could possibly be adminis-
tered without sedation to cats confined in a humane
trap. This obviates the need for veterinarians to be
directly involved with each cat targeted in a population
control campaign, a distinct advantage in parts of the
1524 J.K. Levy et al. / Theriogenology 76 (2011) 1517–1525
world where veterinary services for companion animal
species are not universally available. These findings
suggest that GnRH immunocontraception is an ideal
candidate for further development for the control of
feral cats.
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